Skip to main
LMAT
LMAT logo

LeMaitre Vascular (LMAT) Stock Forecast & Price Target

LeMaitre Vascular (LMAT) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 17%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

LeMaitre Vascular Inc. demonstrated a positive financial outlook, evidenced by a gross margin expansion of 110 basis points year-over-year to 70%, attributed to higher average selling prices, manufacturing efficiencies, and an advantageous product mix. In the latest quarter, operating income increased by 12% year-over-year to $16.1 million, resulting in an operating margin of 25%, while revenues grew by 15% both as reported and organically. Furthermore, the company's net income rose by 17% to $13.8 million, and diluted earnings per share reached $0.60, indicating solid growth potential and a strong trajectory for the future.

Bears say

LeMaitre Vascular Inc is facing a negative financial outlook primarily due to a projected decline in operating margin, anticipated to fall to 24% from 25% as a result of seasonal fluctuations. The company has also revised its target for the number of sales representatives downward, from 170 to 165, which could hinder revenue growth. Additionally, a decrease in R&D expenditure to 6% of revenue raises concerns about product innovation and could adversely affect the firm's competitive position amidst regulatory challenges and slower international market adoption.

LeMaitre Vascular (LMAT) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 17% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of LeMaitre Vascular and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About LeMaitre Vascular (LMAT) Forecast

Analysts have given LeMaitre Vascular (LMAT) a Buy based on their latest research and market trends.

According to 6 analysts, LeMaitre Vascular (LMAT) has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $101.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $101.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

LeMaitre Vascular (LMAT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.